2024 Annual Meeting | Industry Therapeutic Update from Novartis: Unlocking the Latest Data: Why Wait? Early Consideration for an Established B-Cell Therapy with Ease of Administration in RMS

Date Wednesday 04/17/24

Time 11:45 AM - 12:45 PM MDT Add To Calendar

Location Colorado Convention Center | Bluebird 2A

Session Format This program will be presented in-person only

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type Industry Therapeutic Update

Director(s) Stephen W. Yeung, DO, Jason W. Freeman, MD

Topic(s) General Neurology, Multiple Sclerosis

Learning Objectives This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2024 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.

CME Available No CME available

Program Materials Program Evaluations

Event Timeline
11:45 AM - 12:45 PM MDT	Speaker	Industry Therapeutic Update from Novartis: Unlocking the Latest Data: Why Wait? Early Consideration for an Established B-Cell Therapy with Ease of Administration in RMS

Faculty Disclosures
Stephen W. Yeung, DO	Dr. Yeung has received personal compensation for serving as an employee of Novartis.
Jason W. Freeman, MD	Dr. Freeman has received personal compensation for serving as an employee of Novartis . Dr. Freeman has stock in Novartis .